Table 1 Baseline characteristics of patients (n = 154)
Characteristics | N (%) |
|---|---|
Median age, years (range) | 54.0 (27.0–79.0) |
Median BMI at diagnosis, kg/m2 (range) | 22.5 (12.9–31.9) |
Median baseline CA-125 level, U/mL (range) | 808.0 (9.0–19,800.0) |
FIGO stage, n (%) | |
 III | 68 (44.2) |
 IV | 86 (55.8) |
ASA score, n (%) | |
 1–2 | 122 (79.2) |
 3–4 | 21 (13.6) |
 Unknown | 11 (7.2) |
Histologic subtype, n (%) | |
 Mucinous | 20 (13.0) |
 Endometrioid | 31 (20.1) |
 Clear cell | 28 (18.2) |
 LGSC | 30 (19.5) |
 Carcinosarcoma | 12 (7.8) |
 Undifferentiated | 20 (13.0) |
 Mixed | 5 (3.3) |
 Anaplastic | 2 (1.3) |
 Transitional | 3 (2.0) |
 Squamous cell carcinoma | 2 (1.3) |
 Ewing’s sarcoma | 1 (0.6) |
Method of diagnosis, n (%) | |
 Ascites cytology | 59 (38.3) |
 Pleural effusion cytology | 14 (9.1) |
 Aspiration biopsy | 31 (20.1) |
 Diagnostic laparoscopy | 24 (15.6) |
 Diagnostic laparotomy | 4 (2.6) |
 Laparoscopy in other hospital | 12 (7.8) |
 Laparotomy in other hospital | 1 (0.6) |
 Others | 5 (3.3) |
 Not diagnosed before NAC | 4 (2.6) |
Confirm the histologic subtype before NAC, n (%) | |
 No | 108 (70.1) |
 Yes | 46 (29.9) |
  HGSC | 5 (3.3) |
  Mucinous | 7 (4.6) |
  Endometrioid | 4 (2.6) |
  Clear cell | 8 (5.2) |
  LGSC | 9 (5.9) |
  Carcinosarcoma | 2 (1.3) |
  Others | 11 (7.1) |
Reasons for performing NAC*, n (%) | |
 Old age / poor ECOG | 24 (15.6) |
 High tumor burden | 106 (68.8) |
 Considered as HGSC before NAC | 8 (5.2) |
 Refer from other hospital after NAC | 5 (3.3) |
 Others | 30 (19.5) |
NAC regimens, n (%) | |
 Paclitaxel + carboplatin | 137 (89.0) |
 Paclitaxel + cisplatin | 6 (3.9) |
 Docetaxel + carboplatin | 8 (5.2) |
 Paclitaxel + carboplatin + bevacizumab | 1 (0.6) |
 Others | 2 (1.3) |
POAC regimens, n (%) | |
 Paclitaxel + carboplatin | 114 (74.0) |
 Paclitaxel + cisplatin | 5 (3.2) |
 Docetaxel + carboplatin | 9 (5.8) |
 Paclitaxel + carboplatin + bevacizumab | 1 (0.6) |
 Others | 17 (11.0) |
 Not done | 8 (5.2) |